Literature DB >> 21156229

Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.

Ulrike Bacher1, Torsten Haferlach, Wolfgang Kern, Tamara Alpermann, Susanne Schnittger, Claudia Haferlach.   

Abstract

To further clarify the transformation from monoclonal gammopathy of undetermined significance (MGUS) to plasma cell myeloma (PCM), we compared interphase fluorescence in situ hybridization (FISH) patterns in 381 MGUS and 301 PCM patients. According to the World Health Organization and the International Myeloma Working Group, a threshold of 10% of bone marrow plasma cells separated MGUS from PCM. After magnetic activated cell sorting for CD138(+) cells, FISH succeeded in 272 of 301 (90.4%) PCM, but in only 302 of 381 (79.3%) MGUS cases (P < 0.001). Cytogenetic alterations were more frequent in PCM (237 of 272; 87.1%) than MGUS (169 of 302; 56.0%; P = 0.0002). PCM showed a median of two cytogenetic alterations (range, 0-9) and MGUS one (range, 0-6). Considering only cases with a yield of plasma cells allowing five or more FISH probes, del(13)(q14) was found in 99 of 251 (39.3%) PCM but in only 59 of 267 (22.1%) MGUS (P = 0.0001), del(17p) in 15 PCM (6.0%) and in 6 MGUS (2.2%) patients (P = 0.029). A t(4;14)/IGH-FGFR3 was detected in 28 PCM (11.1%) and 5 MGUS (1.9%; P < 0.001). The t(11;14)/IGH-CCND1 and the t(14;16)/IGH-MAF showed no significant differences. Cytomorphology detected higher numbers of plasma cells than multiparameter flow cytometry (median ratio 4.25). This study underlines the genetic heterogeneity of MGUS similar to PCM. Genetic analysis might contribute to more diversified monitoring strategies for MGUS patients.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156229     DOI: 10.1016/j.cancergencyto.2010.08.006

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Utility of a column-free cell sorting system for separation of plasma cells in multiple myeloma FISH testing in clinical laboratories.

Authors:  Shashirekha Shetty; Marion Siady; Kalyan C Mallempati; Andrew Wilson; Jeff Poarch; Brandon Chandler; Judy Gray; Mohamed E Salama
Journal:  Int J Hematol       Date:  2012-02-11       Impact factor: 2.490

2.  Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma.

Authors:  Thomas Smol; Annika Dufour; Sabine Tricot; Mathieu Wemeau; Laure Stalnikiewicz; Franck Bernardi; Christine Terré; Benoît Ducourneau; Hervé Bisiau; Agnès Daudignon
Journal:  Mol Cytogenet       Date:  2017-07-01       Impact factor: 2.009

3.  Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study.

Authors:  Ling Ma; Shuang Xu; Jianhua Qu; Jian Hou; Yang Wang; Lei Wen; Yang Liu; Ying Kang; Ming Jiang; Weijun Fu; Juan Du; Lin Zhou; Xiaojun Huang; Zhaoxia Zhang; Jin Lu
Journal:  Hematol Oncol       Date:  2018-10-01       Impact factor: 5.271

4.  Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias.

Authors:  Ekaterina Rebmann Chigrinova; Naomi A Porret; Thomas Pabst; Ulrike Bacher; Martin Andres; Gertrud Wiedemann; Yara Banz; Myriam Legros; Matthias Pollak; Elisabeth Oppliger Leibundgut
Journal:  BMC Med Genomics       Date:  2022-09-23       Impact factor: 3.622

5.  Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma.

Authors:  V Grossmann; U Bacher; V Artusi; A Kohlmann; N Nadarajah; W Kern; S Schnittger; T Haferlach; C Haferlach
Journal:  Blood Cancer J       Date:  2012-08-31       Impact factor: 11.037

6.  Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response.

Authors:  Svitlana Demyanets; Alexandra Kaider; Ingrid Simonitsch-Klupp; Günther Bayer; Almira Subasic; Renate Thalhammer; Harald Esterbauer; Maria T Krauth; Hermine Agis; Thomas Reiter; Ilse Schwarzinger
Journal:  Ann Hematol       Date:  2020-09-15       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.